Impact News +++ AKTIE IM FOKUS: Norma sacken vorbörslich ab - Vorsichtiger Ausblick (DPA-AFX) +++ NORMA GROUP Aktie +9,66%

Q32 BIO Aktie

>Q32 BIO Aktienkurs

5.35 EUR +2.9% (TradegateBSX)

Ask: 5.45 EUR / 1138 Stück

Bid: 5.3 EUR / 1197 Stück

Tagesumsatz: 18 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Q32 BIO Aktie über LYNX handeln

Intraday

1 Jahr

>Q32 BIO Performance

1 Woche: +6,1%

1 Monat: +48,3%

3 Monate: +125,7%

6 Monate: +266,7%

1 Jahr: +281,7%

laufendes Jahr: +125,7%

>Q32 BIO Aktie

Name:

Q32 BIO INC. O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7469641051 / A4ZZ0Z

Symbol/ Ticker:

DB0 (Frankfurt) / QTTB (NASDAQ)

Kürzel:

FRA:DB0, ETR:DB0, DB0:GR, NASDAQ:QTTB

Index:

Webseite:

https://www.q32bio.com/

Profil:

Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on be..
>Volltext..

Marktkapitalisierung:

92.17 Mio. EUR

Unternehmenswert:

63.53 Mio. EUR

Umsatz:

46.7 Mio. EUR

EBITDA:

15.03 Mio. EUR

Nettogewinn:

25.91 Mio. EUR

Gewinn je Aktie:

2.01 EUR

Schulden:

13.33 Mio. EUR

Liquide Mittel:

41.97 Mio. EUR

Operativer Cashflow:

-29.15 Mio. EUR

Bargeldquote:

4.26

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

Q32 BIO

Letzte Datenerhebung:

31.03.26

>Q32 BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 14.63 Mio. St.

Frei handelbar: 41.27%

Leerverk. Aktien: 2.4%

Rückkaufquote: -

Mitarbeiter: 24

Umsatz/Mitarb.: 1.95 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 95.28%

Bewertung:

KGV: 3.19

KGV lG: -

KUV: 1.77

KBV: 2.25

PEG-Ratio: -

EV/EBITDA: 4.23

Rentabilität:

Bruttomarge: 99.27%

Gewinnmarge: 55.49%

Operative Marge: 31.46%

Managementeffizenz:

Gesamtkaprendite: 38.7%

Eigenkaprendite: 125.06%

>Q32 BIO Peer Group

Gesundheit, Autoimmunerkrankungen, Antikörper- Behandlung

>Q32 BIO Chart & Kurs - NASDAQ

>Q32 BIO News

30.03.26 - 17:30	Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect? (Zacks)
	The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

19.03.26 - 18:45	Q32 Bio (QTTB) Upgraded to Strong Buy: Here′s What You Should Know (Zacks)
	Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

13.03.26 - 16:30	Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? (Zacks)
	The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

10.03.26 - 12:00	Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2......

28.02.26 - 03:01	Insiderhandel: Chief Scientific Officer verkauft Aktien von Q32 Bio im Wert von 12708 USD (Insiderkauf)
	Violette, Shelia M. - Vorstand - Tag der Transaktion: 2026-02-25...

28.02.26 - 03:01	Insiderhandel: CFO and President verkauft Aktien von Q32 Bio im Wert von 18035 USD (Insiderkauf)
	Kalowski, Lee - Vorstand - Tag der Transaktion: 2026-02-25...

28.02.26 - 03:01	Insiderhandel: CEO verkauft Aktien von Q32 Bio im Wert von 44675 USD (Insiderkauf)
	Morrison, Jodie Pope - Vorstand - Tag der Transaktion: 2026-02-25...

19.02.26 - 23:33	Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others \| DelveInsight (PR Newswire)
	The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio),......

18.02.26 - 13:01	Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire)
	WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will......

05.12.25 - 02:01	Insiderhandel: CEO verkauft Aktien von Q32 Bio im Wert von 77871 USD (Insiderkauf)
	Morrison, Jodie Pope - Vorstand - Tag der Transaktion: 2025-12-02...

05.12.25 - 02:01	Insiderhandel: CFO and President verkauft Aktien von Q32 Bio im Wert von 31395 USD (Insiderkauf)
	Kalowski, Lee - Vorstand - Tag der Transaktion: 2025-12-02...

01.12.25 - 14:36	Q32 Bio: Aktie schießt nach Verkauf von Phase-2-Komplementinhibitor an Akebia in die Höhe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 13:03	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire)
	-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million......

01.12.25 - 13:03	Akebia Announces Establishment of Rare Kidney Disease Pipeline (GlobeNewswire EN)
	Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio...

13.11.25 - 13:30	Q32 Bio GAAP EPS of -$0.60 beats by $0.59 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 13:01	Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0......

21.10.25 - 13:01	Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata (PR Newswire)
	-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for......

29.08.25 - 05:01	Insiderhandel: CFO and President verkauft Aktien von Q32 Bio im Wert von 7636 USD (Insiderkauf)
	Kalowski, Lee - Vorstand - Tag der Transaktion: 2025-08-26...

29.08.25 - 05:01	Insiderhandel: Chief Scientific Officer verkauft Aktien von Q32 Bio im Wert von 5385 USD (Insiderkauf)
	Violette, Shelia M. - Vorstand - Tag der Transaktion: 2025-08-26...

29.08.25 - 05:01	Insiderhandel: CEO verkauft Aktien von Q32 Bio im Wert von 18900 USD (Insiderkauf)
	Morrison, Jodie Pope - Vorstand - Tag der Transaktion: 2025-08-26...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Beim Wirt muß man das Lachen bezahlen. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram